InsidersTradesSigma
Total declarations
Company
▲ Purchases (1 ops.)
▼ Sales (0 ops.)
Insider track record
Board DirectorDisclosed buys
1
Disclosed sells
0
T+90 hit rate
50%
T+90 mean return
+1.9%
Across 2 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the complete record of transactions filed by Saad Mark E, Director. Director active across 1 company, notably Axsome Therapeutics, Inc.. Cumulatively, 5 disclosures have been logged. Split: 1 buy · 0 sell. Total volume traded: €92k. Activity tracked since 17 November 2021. The latest transaction was disclosed on 31 December 2025 (Levée d'options). Regulator: SEC (Form 4). The full history is free.
Declarations5 total
1,429 sharesCommon StockSEC:0001193125-26-266436:0
6,231 shares@ US$8.0217.6% of flowCommon StockSEC:0001193125-26-001181:0
9,127 shares@ US$9.0035.5% of flowCommon StockSEC:0000950170-25-113311:0
11,016 shares@ US$3.6716.7% of flowCommon StockSEC:0000950170-24-105616:0
3,000 shares@ US$34.53240.0010% mcap50.0% of flowCommon StockSEC:0001209191-21-065696:0
Canonical exit: 15 Feb 2022 (T+90)
5 of 5 declarations
About Saad Mark E
Saad Mark E is a Board Member of Axsome Therapeutics, Inc. He plays a key role in the governance of the company, contributing to strategic decision-making and oversight of operations. His experience in the pharmaceutical sector is an asset for Axsome Therapeutics, which focuses on developing innovative treatments.
